The largest database of trusted experimental protocols
> Procedures > Laboratory Procedure > Microarray Analysis

Microarray Analysis

Microarray Analysis is a powerful molecular biology technique that enables the simultaneous measurement of expression levels for thousands of genes.
This high-throughput approach provides a comprehensive view of gene activity, allowing researchers to investigate complex biological processes and identify disease-related patterns.
By analyzing the expression profiles of multiple genes, Microarray Analysis facilitates the discovery of novel genetic markers, the elucidation of regulatory networks, and the development of personalized diagnostic and therapeutic strategies.
However, the effective application of this technology requires carefull selection of appropriate protocols and analysis methods to ensure reproducibility and accuracy of the results.
PubCompare.ai, an AI-driven platform, optimizes Microarray Analaysis by helping users find the best protocols from literature, pre-prints, and patents.
Leveraging AI-driven comparisons, PubCompare.ai enhances reproducibility and research accuracy, ensuring your Microarray Analysis is precise and reliable.

Most cited protocols related to «Microarray Analysis»

Figure 3 shows example diagnostic plots. Panel (A) shows RNA-seq data from Pickrell et al. (9 (link)) that has been analysed as described by Law et al. (10 (link)). Panels (B) and (C) display the two-colour microarray quality control data set presented by Ritchie et al. (11 (link)). Panel (B) displays background corrected but non-normalized intensities from one typical array. Panel (C) was generated from a subset of 30 of the control arrays after print-tip loess normalization (12 ).
Figure 4 shows example DE summary plots. Panels (A) and (B) were generated using the two-colour microarray data from GEO series GSE2593. Intensities were background corrected and normalized as previously described (13 (link)). Panel (A) shows a volcano plot for the comparison of samples with RUNX1 over-expressed versus wild-type samples, while panel (B) shows a Venn diagram of differentially expressed probes for each of the three over-expressed genes versus wild-type. Probes with false discovery rate less than 0.05 were considered to be differentially expressed. Panel (C) uses RNA-seq data from GEO series GSE52870. The data were analysed as described in Figure 5 of Liu et al. (7 (link)).
Full text: Click here
Publication 2015
Diagnosis Genes Microarray Analysis RNA-Seq RUNX1 protein, human
Genome-wide expression was measured in liver and kidney using RNA-seq on the Illumina GA I and hybridization of the same samples to Affymetrix HG-U133 Plus 2.0 arrays. The sample preparation and data analysis was designed to maximize the similarity between the microarray and RNA-seq experiments (see Marioni et al. [21 (link)]). Differential expression between kidney and liver was determined using an empirical Bayes modified t-statistic on the microarray platform and P-values for DE were downloaded from their website. For the RNA-seq experiment, the data were normalized using TMM normalization [27 ] and a negative binomial exact test was used to determine DE [16 (link)]. To test the GOseq method, we used the genes called DE from the microarray experiment to calculate the significance of over-representation of each GO category using the standard GO analysis methods. We also calculated P-values for each GO category being over-represented among genes that were DE in the RNA-seq data, using both the GOseq and hypergeometric methods. GOseq's ability to outperform the hypergeometric method, as measured by its ability to reproduce the results of the microarray GO analysis, was quantified by calculating a P-value for the difference in the two methods being due to chance. To do this, a NULL was chosen under which both methods were equally likely to correctly recover each microarray GO category, with this likelihood given by a binomial distribution.
Full text: Click here
Publication 2010
Crossbreeding Genes Genome Kidney Liver Microarray Analysis RNA-Seq
KOBAS 2.0 has two consecutive programs ‘annotate’ and ‘identify’, which is similar to KOBAS 1.0 (1 (link),2 (link)). The first program ‘annotates’ each input gene with putative pathways and diseases by mapping the gene to genes in KEGG GENES or terms in KO which are linked to pathway and disease terms in backend databases. For ID mapping, input IDs are mapped directly to genes using the cross-links we parsed from KEGG GENES. Then, if necessary, IDs are mapped to KO terms. For sequence similarity mapping, each input sequence is BLASTed against all sequences in KEGG GENES. The default cutoffs are BLAST E-value <10−5 and rank ≤5. They mean that an input sequence is assigned KO term(s) of the first BLAST hit that (i) has known KO assignments; (ii) has BLAST E-value <10−5; and (iii) has less than five other hits with a lower E-value that do not have KO assignments (1 (link)). A new option in KOBAS 2.0 is that users can map against genes in user-specified species instead of all genes by BLASTing against only sequences of the user-specified species. In order to reduce possible false positives due to multidomain proteins, we added a new option to allow users to set a cutoff of BLAST subject coverage. Another new option allows users to restrict sequence mapping to only orthologs as defined by Ensembl Compara (38 (link)).
The second program ‘identifies’ statistically significantly enriched pathways and diseases by comparing results from the first program against the background (usually genes from the whole genome, or all probe sets on a microarray). Users can define their own background distribution in KOBAS 2.0 (for example, result from the first program to ‘annotate’ all probe sets on a microarray). If users do not upload a background file, KOBAS 2.0 uses the genes from whole genome as the default background distribution. Here, we consider only pathways and diseases for which there are at least two genes mapped in the input. Users can choose to perform statistical test using one of the following four methods: binomial test, chi-square test, Fisher's exact test and hypergeometric test, and perform FDR correction. The purpose of performing FDR correction is to reduce the Type-1 errors. When a large number of pathway and disease terms are considered, multiple hypotheses tests are performed, which leads to a high overall Type-1 error even for a relatively stringent P-value cutoff. KOBAS 1.0 supports the FDR correction method QVALUE (39 ). In KOBAS 2.0, we add two more popular FDR correction methods: Benjamini-Hochberg (40 ) and Benjamini-Yekutieli (41 ).
Publication 2011
Chromosome Mapping Genes Genome Microarray Analysis Proteins
A complete technical description of the prediction pipeline implemented in the pRRophetic package is described in [1] (link). Briefly, microarray probes are (when possible) first remapped to the latest build of EntrezGene. Training and test expression data are quantile normalized separately and subsequently combined by standardizing the mean and variance of each gene using an empirical Bayesian approach. Genes with very low variability across samples are removed. A ridge regression model is fit to the training expression data using all remaining genes as predictors and the drug sensitivity (IC50) values (of the drug of interest) as the outcome variable. Finally, this model is applied to the processed, standardized, filtered clinical tumor expression data, yielding a drug sensitivity estimate for each patient. All R source code is publicly available via GitHub and on our website (see “Availability” section).
Full text: Click here
Publication 2014
Genes Genetic Diversity Hypersensitivity Microarray Analysis Neoplasms Patients Pharmaceutical Preparations
To assess a transcript's coding potential, we extract six features from the transcript's nucleotide sequence. A true protein-coding transcript is more likely to have a long and high-quality Open Reading Frame (ORF) compared with a non-coding transcript. Thus, our first three features assess the extent and quality of the ORF in a transcript. We use the framefinder software (14 ) to identify the longest reading frame in the three forward frames. Known for its error tolerance, framefinder can identify most correct ORFs even when the input transcripts contain sequencing errors such as point mutations, indels and truncations (14 ,15 (link)). We extract the LOG-ODDS SCORE and the COVERAGE OF THE PREDICTED ORF as the first two features by parsing the framefinder raw output with Perl scripts (available for download from the web site). The LOG-ODDS SCORE is an indicator of the quality of a predicted ORF and the higher the score, the higher the quality. A large COVERAGE OF THE PREDICTED ORF is also an indicator of good ORF quality (14 ). We add a third binary feature, the INTEGRITY OF THE PREDICTED ORF, that indicates whether an ORF begins with a start codon and ends with an in-frame stop codon.
The large and rapidly growing protein sequence databases provide a wealth of information for the identification of protein-coding transcript. We derive another three features from parsing the output of BLASTX (16 (link)) search (using the transcript as query, E-value cutoff 1e-10) against UniProt Reference Clusters (UniRef90) which was developed as a nonredundant protein database with a 90% sequence identity threshold (17 (link)). First, a true protein-coding transcript is likely to have more hits with known proteins than a non-coding transcript does. Thus we extract the NUMBER OF HITS as a feature. Second, for a true protein-coding transcript the hits are also likely to have higher quality; i.e. the HSPs (High-scoring Segment Pairs) overall tend to have lower E-value. Thus we define feature HIT SCORE as follows:

where Eij is the E-value of the j-th HSP in frame i, Si measures the average quality of the HSPs in frame i and HIT SCORE is the average of Si across three frames. The higher the HIT SCORE, the better the overall quality of the hits and the more likely the transcript is protein-coding. Thirdly, for a true protein-coding transcript most of the hits are likely to reside within one frame, whereas for a true non-coding transcript, even if it matches certain known protein sequence segments by chance, these chance hits are likely to scatter in any of the three frames. Thus, we define feature FRAME SCORE to measure the distribution of the HSPs among three reading frames:

The higher the FRAME SCORE, the more concentrated the hits are and the more likely the transcript is protein-coding.
We incorporate these six features into a support vector machine (SVM) machine learning classifier (18 ). Mapping the input features onto a high-dimensional feature space via a proper kernel function, SVM constructs a classification hyper-plane (maximum margin hyper-plane) to separate the transformed data (18 ). Known for its high accuracy and good performance, SVM is a widely used classification tool in bioinformatics analysis such as microarray-based cancer classification (19 (link),20 (link)), prediction of protein function (21 (link),22 (link)) and prediction of subcellular localization (23 (link),24 (link)). We employed the LIBSVM package (25 ) to train a SVM model using the standard radial basis function kernel (RBF kernel). The C and gamma parameters were determined by grid-search in the training dataset. We trained the SVM model using the same training data set as CONC used (13 (link)), containing 5610 protein-coding cDNAs and 2670 noncoding RNAs.
Publication 2007
Amino Acid Sequence Base Sequence Codon, Initiator Codon, Terminator DNA, Complementary Gamma Rays Immune Tolerance INDEL Mutation Malignant Neoplasms Microarray Analysis Point Mutation Proteins Reading Frames RNA, Untranslated Staphylococcal Protein A

Most recents protocols related to «Microarray Analysis»

Example 1

As an initial proof of concept, a model system is developed using a microarray to demonstrate a working single-plex assay. The basic design validates the concept of the assay, and establishes a working assay prior to addressing issues related to the analysis of a more complicated biological sample. Conventional sequencing is used as a readout for this proof of concept.

A microarray is used as a proxy for a tissue section. The target sequences of the microarray are fully specified, so that the composition of the targets are known and can be varied systematically. Synthetic oligonucleotide templates are attached to a glass slide via a 5′ amino modification. Each slide has a single oligonucleotide template sequence, and the assays that are carried out may employ either ligation, or extension followed by ligation as this may be useful in determining certain polymorphisms.

Once the in situ part of the assay is complete, the reaction products are eluted and analyzed by qPCR to determined presence or absence of a product and estimate yield, and by conventional sequencing to determine the structure of the assay products. The single plex assays that are tested include appropriate positive and negative controls, and a single nucleotide variant (SNV) to check ability to discriminate single base variants.

Full text: Click here
Patent 2024
Biological Assay Biological Models Biopharmaceuticals Genetic Polymorphism Ligation Microarray Analysis Nucleotides Oligonucleotides Tissues

Example 11

The present Example describes using activatable antibodies to detect expression and/or activation in tissue microarrays (TMAs). The anti-Jagged antibody 4D11 was used with a non-small cell lung cancer (NSCLC) TMA and a breast cancer (BC) TMA. Most of the NSCLC and BC patient tumor samples were positive for Jagged expression. The same NSCLC and BC TMAs were contacted with the activatable anti-Jagged antibody referred to herein as 5342-1204-4D11. 97% of NSCLC and 100% of BC patient tumor samples were positive for binding and activation of 5342-1204-4D11 activatable anti-Jagged antibody. Furthermore, more than 80% of the tumor samples were characterized by a high activation rate (++or +++) as shown in FIG. 21. The same NSCLC and BC TMAs were contacted with the A11 antibody, which binds to the protease MT-SP1. 77% of the NSCLC and 98% of the BC patient tumor samples were positive for MT-SP1 activity. 8 NSCLC tumors lacked MT-SP1 activity, but demonstrated binding and activation of the 5342-1204-4D11 activatable anti-Jagged antibody, which suggests the participation of proteases in the activation of the 5342-1204-4D11 activatable anti-Jagged antibody.

Full text: Click here
Patent 2024
Antibodies Antibodies, Anti-Idiotypic Breast Carcinoma Breast Neoplasm Endopeptidases Immunoglobulins Malignant Neoplasms Microarray Analysis Neoplasms Non-Small Cell Lung Carcinoma Patients Peptide Hydrolases ST14 protein, human Tissues

Example 2

Our microarray data identified CH25H as a STAT1-regulated gene in AD conditions (FIGS. 3A and 3B). Furthermore, we confirmed the regulatory effect of STAT1 on CH25H by real-time PCR, Western Blot and ChIP assay (FIGS. 4A,4B,5A,5B). As shown in FIG. 4A which depicts real-time PCR results, CH25H mRNA expression is significantly reduced in STAT1 deficient mice. As shown in FIG. 4B which depicts Western Blot results, CH25H protein level is also significantly reduced in STAT1 deficient mice. Results from the ChIP assay in FIGS. 5A and 5B also showed that in STAT1 deficient mice, less STAT1 was binding to the CH25H gene promoter sequence. The reduced level of 25-OHC in STAT1 deficient mice further supported the notion that STAT1-CH25H axis controls brain 25-OHC level (FIG. 6A-6B).

Full text: Click here
Patent 2024
Brain Epistropheus Genes Immunoprecipitation, Chromatin Microarray Analysis Mus Promoter, Genetic Proteins Real-Time Polymerase Chain Reaction RNA, Messenger STAT1 protein, human Western Blot
A digoxin-labeled probe (Digoxin-5’- TTCAGCTCTTCAGAAGAGGCCTTGGGAT TGGTTCGCTGCT-3’-Di-goxin) was synthesized for evaluating the circDNAJC11 expression in a tissue microarray (Outdo Biotech, Shanghai, China) containing 269 BC tissues and 134 paracarcinoma tissues. The tissue microarray was dewaxed, rehydrated, digested with proteinase K, and hybridized with the circDNAJC11 probe at 45 °C for 13 h. Afterward, the issues were combined with a biotin-conjugated anti-digoxin antibody for incubation overnight at 4℃, followed by 3,3-diaminobenzidine (DAB) staining. CircDNAJC11 expression was quantified by multiplying the positive staining intensity score (strong = 3, medium = 2, weak = 1, and negative = 0) by the percentage of positive-stained cells (> 76% = 4, 51–75% = 3, 26–50% = 2, 5–25% = 1, and < 5% = 0).
Full text: Click here
Publication 2023
Antibodies, Anti-Idiotypic Biotin Cells Debility Digoxin Endopeptidase K Microarray Analysis Tissues
Venous blood samples will be collected for serum, plasma, DNA, and RNA extraction. Identifying biomarkers relevant to the course of depression is an area of research that is evolving rapidly. Thus, based on an ongoing critical literature review, the search for and analysis of specific biomarkers may change during the study period. Currently, the blood biomarkers include inflammation parameters (e.g., high sensitivity CRP) [61 (link), 62 (link)] and neurotrophic factors (e.g., BDNF and S100B) [63 , 64 (link)].
DNA from blood samples will be used for microarray-based genotyping of MDD candidate genes, genes of relevance for MDD (e.g., rs41271330, 5-HTTLPR, COMT, and BDNFval66met), drug metabolism (e.g., CYP2D6, CYP2C19, UGT1A1, ABCB1, ABCC1) and to compute polygenic risk scores in all participants after genome-wide genotyping in the future. DNA will also be used for epigenetic analysis, and circular extrachromosomal DNA, a form of decomposed free DNA [65 (link)], will be extracted and characterised. RNA will be extracted for gene transcription profiles using microarray or TAG-based methods (mRNA and microRNA).
DNA from blood samples will be used for microarray-based genotyping of MDD candidate genes, genes of relevance for MDD (e.g., rs41271330, 5-HTTLPR, COMT, and BDNFval66met), drug metabolism (e.g., CYP2D6, CYP2C19, UGT1A1, ABCB1, ABCC1) and to compute polygenic risk scores in all participants after genome-wide genotyping in the future. DNA will also be used for epigenetic analysis, and circular extrachromosomal DNA, a form of decomposed free DNA [65 (link)], will be extracted and characterised. RNA will be extracted for gene transcription profiles using microarray or TAG-based methods (mRNA and microRNA).
Gene analyses will be based on a priori models of genetic variations known to modulate pharmacotherapy and psychotherapy responses. The results will be used to calculate a polygenic risk score for diagnosis and treatment response and meta-analyses with established polygenic risk scores for MDD and those currently developed for anxiety and anxiety disorders, including treatment response [66 (link)].
Full text: Click here
Publication 2023
ABCB1 protein, human ABCC1 protein, human Anxiety Anxiety Disorders Biological Markers BLOOD COMT protein, human CYP2C19 protein, human Cytochrome P-450 CYP2D6 Diagnosis DNA, A-Form DNA, Circular Genes Genetic Diversity Genome Hypersensitivity Inflammation Metabolism Microarray Analysis MicroRNAs Nerve Growth Factors Pharmaceutical Preparations Pharmacotherapy Plasma Psychotherapy RNA, Messenger Serum Transcription, Genetic UGT1A1 protein, human Veins

Top products related to «Microarray Analysis»

Sourced in Germany, United States, United Kingdom, Netherlands, Spain, Japan, Canada, France, China, Australia, Italy, Switzerland, Sweden, Belgium, Denmark, India, Jamaica, Singapore, Poland, Lithuania, Brazil, New Zealand, Austria, Hong Kong, Portugal, Romania, Cameroon, Norway
The RNeasy Mini Kit is a laboratory equipment designed for the purification of total RNA from a variety of sample types, including animal cells, tissues, and other biological materials. The kit utilizes a silica-based membrane technology to selectively bind and isolate RNA molecules, allowing for efficient extraction and recovery of high-quality RNA.
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
Sourced in United States, Germany, Canada, China, France, United Kingdom, Japan, Netherlands, Italy, Spain, Australia, Belgium, Denmark, Switzerland, Singapore, Sweden, Ireland, Lithuania, Austria, Poland, Morocco, Hong Kong, India
The Agilent 2100 Bioanalyzer is a lab instrument that provides automated analysis of DNA, RNA, and protein samples. It uses microfluidic technology to separate and detect these biomolecules with high sensitivity and resolution.
Sourced in United States, Germany, China, Japan, United Kingdom, Canada, France, Italy, Spain, Australia, Switzerland, Belgium, Denmark, Netherlands, India, Ireland, Lithuania, Singapore, Sweden, Norway, Austria, Brazil, Argentina, Hungary, Sao Tome and Principe, New Zealand, Hong Kong, Cameroon, Philippines
TRIzol is a monophasic solution of phenol and guanidine isothiocyanate that is used for the isolation of total RNA from various biological samples. It is a reagent designed to facilitate the disruption of cells and the subsequent isolation of RNA.
Sourced in United States, Germany, Japan, United Kingdom
The Feature Extraction software is a tool used to analyze and process data from microarray experiments. It provides a standardized and automated method for extracting meaningful information from raw microarray image data.
Sourced in United States, Germany, Canada, United Kingdom, France, China, Japan, Spain, Ireland, Switzerland, Singapore, Italy, Australia, Belgium, Denmark, Hong Kong, Netherlands, India
The 2100 Bioanalyzer is a lab equipment product from Agilent Technologies. It is a microfluidic platform designed for the analysis of DNA, RNA, and proteins. The 2100 Bioanalyzer utilizes a lab-on-a-chip technology to perform automated electrophoretic separations and detection.
Sourced in Germany, United States, United Kingdom, Spain, Netherlands, Canada, France, Japan, China, Italy, Switzerland, Australia, Sweden, India, Singapore, Denmark, Belgium
The RNeasy kit is a laboratory equipment product that is designed for the extraction and purification of ribonucleic acid (RNA) from various biological samples. It utilizes a silica-membrane-based technology to efficiently capture and isolate RNA molecules.
Sourced in United States, China, United Kingdom
The Human Genome U133 Plus 2.0 Array is a high-density oligonucleotide microarray designed to analyze the expression of over 47,000 transcripts and variants from the human genome. It provides comprehensive coverage of the human transcriptome and is suitable for a wide range of gene expression studies.
Sourced in United States, Germany, Japan, Canada
The Agilent Microarray Scanner is a high-performance instrument designed for the scanning and analysis of microarray data. It provides automated image acquisition and data extraction capabilities for a wide range of microarray applications.
Sourced in Germany, United States, United Kingdom, Netherlands, China, Canada, Spain, Japan, Italy, France, Australia, Norway, Denmark, Sweden, Belgium
The MiRNeasy Mini Kit is a laboratory instrument designed for the extraction and purification of microRNA (miRNA) and other small RNA molecules from a variety of sample types, including cells, tissues, and body fluids. The kit utilizes a silica-membrane-based technology to facilitate the efficient isolation of high-quality miRNA and small RNA.

More about "Microarray Analysis"

Microarray Analysis, also known as DNA Microarray or Gene Expression Profiling, is a cutting-edge molecular biology technique that allows researchers to simultaneously measure the expression levels of thousands of genes.
This high-throughput approach provides a comprehensive understanding of gene activity, enabling the investigation of complex biological processes and the identification of disease-related patterns.
By analyzing the expression profiles of multiple genes, Microarray Analysis facilitates the discovery of novel genetic markers, the elucidation of regulatory networks, and the development of personalized diagnostic and therapeutic strategies.
This powerful technology is commonly used in fields such as genomics, transcriptomics, and personalized medicine.
To ensure the accuracy and reproducibility of Microarray Analysis, researchers often utilize tools like the RNeasy Mini Kit, TRIzol reagent, and the Agilent 2100 Bioanalyzer for sample preparation and quality control.
The Feature Extraction software and the Agilent Microarray Scanner are also frequently employed to process and analyze the microarray data.
In addition to these tools, the Human Genome U133 Plus 2.0 Array and the MiRNeasy Mini Kit are widely used in Microarray Analysis for the comprehensive profiling of gene and microRNA expression, respectively.
PubCompare.ai, an AI-driven platform, optimizes Microarray Analysis by helping users find the best protocols from literature, pre-prints, and patents.
Leveraging AI-driven comparisons, PubCompare.ai enhances reproducibility and research accuracy, ensuring your Microarray Analysis is precise and realible.